Trinity Biotech Corp - חוב לטווח קצר של החברה TRIB

Stable cash flow from diabetes monitoring and HIV tests offsets debt costs for Trinity Biotech plc (TRIB). Short-term borrowing levels reflect capital refinancing dynamics, with the value stabilizing at 0.00. The outlook for Trinity Biotech plc (TRIB) relies on patents that create customer dependency on consumables, alongside the Irish holding company's robust R&D potential in AI analyzers.

Short-term debt aggregates all obligations with a maturity of up to one year, allowing investors to assess liquidity risk and working capital management efficiency through the level of short-term liabilities. This calculation trend reflects the balance between current borrowings and operating cash flow, which is critical for Trinity Biotech plc (TRIB) when settling payments with external suppliers of reagents and plastics.